Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.

Revenue
+58.0%
EPS
+110.7%
Free cash flow
+411.2%
Total debt
−2.25%

Quarter to September 2026, against a year earlier

224.21 4.23 +1.92%
Market cap
$13.0B
P/E
0.0×
Fwd P/E
−803×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
12.73 11.33 13.41 14.06
P/FCF ratio
0.00 0.00 0.00 269.42
P/Operating CF
943.64 (498.69) 554.57 251.61
P/B ratio
9.84 9.31 12.04 13.53
EV/Sales
12.86 11.46 13.51 14.07
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(167.07) (180.03) (678.98) 269.68
Current Ratio
4.69 5.43 5.04 4.57
Net Debt/EBITDA
1.66 29.18 30.16 (25.55)
Debt/Equity
0.10 0.10 0.10 0.09
Earnings Yield
(2.89%) (3.05%) (2.33%) (1.79%)
Free Cash Flow Yield
(0.60%) (0.56%) (0.15%) 0.37%
Free Cash Flow per Share
0.07 (0.28) 0.21 0.62
Book value per Share
11.47 11.56 11.60 12.14
Free Cash Flow
3.93 (16.48) 12.09 36.49
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026